Overview

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Status:
Completed
Trial end date:
2014-11-10
Target enrollment:
Participant gender:
Summary
To examine efficacy and safety after 12-week administration of ASP7991 in secondary hyperparathyroidism patients undergoing hemodialysis
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
ASP7991
Cinacalcet
Cinacalcet Hydrochloride